Bayer AG (BAYRY) Stock Price & Analysis
Bayer AG (BAYRY) — price $12.69 (+3.17%), as of the Oct 26, 2026 trading session; market cap $49.9B. Expected results Nov 3, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Bayer AG · BAYRY · Healthcare · Drug Manufacturers - General
Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science.
Price as of Oct 26, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $12.69 | |
| Change on the day | +3.17% | |
| 52-week range | $7.48 – $15.23 | |
| Market capitalisation | $49.9B | |
| Shares traded on the day | 115.0K | |
| Beta (volatility vs the S&P 500) | 0.83 | |
| Dividends per share (last 12 months) | $0.03 | |
| Dividend yield (last 12 months) | 0.26% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · in line with the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextOther perspectives
Council score for Bayer AG (BAYRY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
0 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read date unavailable · not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 26, 2026, except a card that shows its own read date.
Watch the BAYRY film — every key number, told as a short cinematic story
~2 min · open the film
What is Bayer AG (BAYRY), and what does it report?
Short answer · as of
Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science. Healthcare / Drug Manufacturers General Headquarters: Kaiser-Wilhelm-Allee 1, Leverkusen, NW, 51368, DE. It employs 88,078 people and is led by Bill Anderson. In Q2 FY2026 it reported revenue of $12.15B and net income of $245M. The market values it at $49.9B.
What do the latest results show for Bayer AG (BAYRY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $12.15B. Against analyst estimates the company has EPS beat 6 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $12.53B Aug 4, 2026
- Latest report · revenue estimate
- $12.31B Aug 4, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 4, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 4, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 4, 2026 | $12.53B | $12.31B | $0.2900 | $0.2300 |
| May 12, 2026 | $15.73B | $15.77B | $0.7900 | $0.6400 |
| Mar 4, 2026 | $13.31B | $13.11B | $0.1800 | $0.1800 |
| Nov 12, 2025 | $13.22B | $13.09B | $0.1700 | $0.1300 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $12.15B | $245M | $0.06 (diluted) |
| Q1 FY2026 | $15.23B | $3.14B | $0.79 (diluted) |
| Q4 FY2025 | $12.66B | -$4.16B | -$1.05 (diluted) |
| Q3 FY2025 | $10.80B | -$1.07B | -$0.28 (diluted) |
What are the financial strengths and risks for Bayer AG (BAYRY)?
Short answer
The distress and quality screens read Altman Z 0.94 · Piotroski F 3. Trailing ratios: ROE -7.5% · ROA -2.0% · current ratio 1.06 · earnings yield -6.1% · free-cash-flow yield 5.7%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 0.94 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-7.5%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at Bayer AG (BAYRY)?
Short answer · as of
The next earnings report is expected on Nov 3, 2026.
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How is Bayer AG scored?
Research dated 2026-09-12.
A focused pharmaceutical manufacturer primarily exposes investors to medicine development and commercialization. Bayer places that activity beside branded consumer health and a broad agricultural platform spanning seeds, crop protection, plant traits, and farming tools.
That structure creates distinct customer and distribution paths inside the same group: hospitals and pharmacies for therapies, retailers for self-care, and direct agricultural sales for farm products. The comparison is therefore closer to a diversified life-sciences portfolio than to a pure drugmaker, despite Bayer’s healthcare classification.
| Company | Price | Market value | Score |
|---|---|---|---|
| $39.59 Oct 23, 2026 | $41.7B | — Model unavailable | |
| $17.50 Oct 26, 2026 | $31.4B | — Model unavailable | |
| $99.68 Oct 26, 2026 | $43.1B | — Model unavailable | |
| $46.86 Oct 23, 2026 | $26.4B | — Model unavailable | |
| $27.10 Oct 26, 2026 | $26.5B | — Model unavailable | |
| $250.69 Oct 23, 2026 | $37.0B | — 5-pillar · not comparable | |
| $41.65 Oct 26, 2026 | $99.9B | — 5-pillar · not comparable | |
| $50.75 Oct 23, 2026 | $102B | — 5-pillar · not comparable | |
| $61.28 Oct 26, 2026 | $125B | — 5-pillar · not comparable | |
| $30.03 Oct 23, 2026 | $171B | — 5-pillar · not comparable | |
| $156.04 Oct 23, 2026 | $193B | — 5-pillar · not comparable | |
| $444.63 Oct 26, 2026 | $240B | — 5-pillar · not comparable |
The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 0.2% Period end Jun 30, 2026
- Previous quarter · ownership
- 0.2% Prior to period end Jun 30, 2026
- Reporting holders
- 15 Period end Jun 30, 2026
- Previous quarter · holders
- 16 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Kahn Brothers Group INC | 6,518,603 |
| Great Lakes Advisors, LLC | 126,119 |
| Rhumbline Advisers | 68,922 |
| Gamma Investing LLC | 41,204 |
| Atlas Capital Advisors INC. | 34,746 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What Investors Ask About Bayer AG (BAYRY) — Healthcare
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why is Bayer not simply a pharmaceutical company?
Prescription medicines are only part of Bayer’s commercial base. Consumer self-care and Crop Science add retail products, seeds, crop protection, plant traits, and farming tools sold through different channels to different buyers.
What is the BAYRY stock price today?
The last price recorded on this page for Bayer AG (BAYRY) is $12.69, as of the Oct 26, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Does BAYRY pay a dividend?
Yes. Bayer AG (BAYRY) shows a trailing 12-month dividend yield of 0.26%, as of Oct 23, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (49 figures)
The 49 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 40 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $12.69 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-26T20:14:47.156Z. | |
px.change | Change on the day | +3.17% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $49.9B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-26. FMP quote timestamp: 2026-10-26T19:59:23.000Z. Captured from FMP at 2026-10-26T20:14:46.236Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Nov 3, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | +$0.39 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 115.0K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.83 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Drug Manufacturers General | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, 51368, DE | FMP | Financial Modeling Prep (FMP) company profile | |
id.employees | Employees | 88,078 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Bill Anderson | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q2 FY2026 | $12.15B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | $245M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-08-04.revenue_actual | Revenue · reported — report date 2026-08-04 | $12.53B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.revenue_estimated | Revenue · estimate — report date 2026-08-04 | $12.31B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.eps_actual | EPS · reported — report date 2026-08-04 | $0.2900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.eps_estimated | EPS · estimate — report date 2026-08-04 | $0.2300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-12.revenue_actual | Revenue · reported — report date 2026-05-12 | $15.73B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-12.revenue_estimated | Revenue · estimate — report date 2026-05-12 | $15.77B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-12.eps_actual | EPS · reported — report date 2026-05-12 | $0.7900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-12.eps_estimated | EPS · estimate — report date 2026-05-12 | $0.6400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-04.revenue_actual | Revenue · reported — report date 2026-03-04 | $13.31B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-04.revenue_estimated | Revenue · estimate — report date 2026-03-04 | $13.11B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-04.eps_actual | EPS · reported — report date 2026-03-04 | $0.1800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-04.eps_estimated | EPS · estimate — report date 2026-03-04 | $0.1800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-12.revenue_actual | Revenue · reported — report date 2025-11-12 | $13.22B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-12.revenue_estimated | Revenue · estimate — report date 2025-11-12 | $13.09B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-12.eps_actual | EPS · reported — report date 2025-11-12 | $0.1700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-12.eps_estimated | EPS · estimate — report date 2025-11-12 | $0.1300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
own.institutions.depth.ownership_pct | Institutional ownership | 0.2% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 0.2% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 15 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 16 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Kahn Brothers Group INC — shares in provider snapshot | 6,518,603 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Great Lakes Advisors, LLC — shares in provider snapshot | 126,119 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Rhumbline Advisers — shares in provider snapshot | 68,922 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Gamma Investing LLC — shares in provider snapshot | 41,204 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Atlas Capital Advisors INC. — shares in provider snapshot | 34,746 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $7.48 – $15.23 | UNRECORDED | Stored company-profile observation — Captured 2026-10-26 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 6 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-17 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 0.94 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-26 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -7.5% · ROA -2.0% · current ratio 1.06 · earnings yield -6.1% · free-cash-flow yield 5.7% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 4 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.03 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 1 split-adjusted declared dividend with an ex-date in the 365 days to 2026-10-26, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 0.26% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-08-04.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($12.53B) with the recorded estimate ($12.31B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-04.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.2900) with the recorded estimate ($0.2300) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 1 fact from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-08-04. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-04.revenue_actual,earn.history.depth.2026-08-04.revenue_estimated,earn.history.depth.2026-08-04.revenue_actual.comparison,earn.history.depth.2026-08-04.eps_actual.comparison,earn.history.depth.2026-08-04.eps_actual,earn.history.depth.2026-08-04.eps_estimated,earn.history.depth.2026-05-12.revenue_actual,earn.history.depth.2026-05-12.revenue_estimated,earn.history.depth.2026-05-12.eps_actual,earn.history.depth.2026-05-12.eps_estimated,earn.history.depth.2026-03-04.revenue_actual,earn.history.depth.2026-03-04.revenue_estimated,earn.history.depth.2026-03-04.eps_actual,earn.history.depth.2026-03-04.eps_estimated,earn.history.depth.2025-11-12.revenue_actual,earn.history.depth.2025-11-12.revenue_estimated,earn.history.depth.2025-11-12.eps_actual,earn.history.depth.2025-11-12.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Sector / industry (provider taxonomy) | Healthcare / Drug Manufacturers - General | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Business description | Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division concentrates on developing and marketing prescription medications, with key areas including cardiology and women's healthcare. It also offers specialized therapeutic solutions for oncology, hematology, and ophthalmology, alongside diagnostic imaging equipment, contrast agents, and advanced cell and gene therapies. Bayer's Consumer Health segment provides a wide array of non-prescription (over-the-counter) medicines, medical devices, medicated skincare items, and nutritional supplements. These self-care products address diverse health needs such as dermatology, dietary support, pain relief, cardiovascular risk prevention, digestive issues, allergy management, and cold and cough symptoms. The Crop Science division supports the agricultural sector with chemical and biological crop protection products, genetically enhanced plant traits, seeds, digital farming tools, and solutions for pest and weed control. This segment also manages the breeding, propagation, production, and specialized treatment of seeds, complemented by dedicated customer service for farmers. Bayer is actively involved in numerous strategic collaborations to bolster its research and development pipeline. These partnerships include an agreement with MD Anderson Cancer Center for oncology drug development, a research and licensing deal with Dewpoint Therapeutics, Inc. focused on novel treatments for cardiovascular and gynecological diseases, and collaborations with Exscientia Ltd, Foundation Medicine Inc., Evotec AG, and Arvinas Inc. Additionally, the company maintains strategic research alliances with the University of Oxford for gynecological therapies and with Kyoto University to discover potential new drugs for pulmonary conditions. The company’s products reach a broad market through various distribution channels, including wholesale partners, independent and chain pharmacies, supermarkets, online and other retail outlets, hospitals, and direct sales to agricultural producers. Bayer Aktiengesellschaft was established in 1863 and is headquartered in Leverkusen, Germany. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Employees | Count: 88,078 | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Named officers | CEO: Bill Anderson; Officers: Rodrigo Santos — Title: Member of Management Board, Head of the Crop Science Division & President of Crop Science Division, Pay: $2.65M, Born: 1973; William N. Anderson — Title: Chairman of the Management Board & Chief Executive Officer, Pay: $6.56M, Born: 1966; Heike Prinz — Title: Chief Talent Officer, Labor Director & Member of Management Board, Pay: $2.77M, Born: 1964; Jana Marlen Ackermann — Title: Head of the Investor Relations, Born: 1984; Jost Reinhard — Title: President of the Radiology Business for Pharmaceuticals Division, Born: 1972; Alex Buschermohle — Title: Chief Information Officer, Head-Digital Transformation & IT-Crop Science Division; Daniella Foster — Title: SVP and Global Head of Public Affairs,Science & Sustainability for Bayer's Consumer Health Division; Stefan Oelrich — Title: President of the Pharmaceuticals Division & Member of the Board of Management, Pay: $2.57M, Born: 1968 Titles and pay come from the company's proxy statement as our provider parsed it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) |
Data provided for informational purposes only.